When is the best time to take Ruxolitinib?

Ruxolitinib tablets are indicated for the treatment of high-risk and intermediate-risk myelofibrosis (MF) (primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF). This drug may also be used in patients with grade 1 risk MF (primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF) with severe disease-related symptoms who are resistant or refractory to other available therapies, or who are unable to tolerate these therapies.

Patients need to undergo a complete blood count before treatment with ruxolitinib tablets, and doctors will ask about past infections, including tuberculosis, herpes simplex, herpes zoster, and hepatitis B. Physicians will perform a complete blood count every 2-4 weeks until the dose is stable, and then as clinically indicated, and assess lipid parameters approximately 8-12 weeks after starting ruxolitinib tablets treatment. When ruxolitinib therapy is discontinued for reasons other than thrombocytopenia, a gradual reduction of the ruxolitinib dose to, for example, 5 mg twice per day may be considered.

Ruxolitinib tabletsThe original drug has been launched in China and is included in the scope of Class B medical insurance. It is limited to patients who meet the indications. Specification The price of each box of 5mg*60 tablets may be around RMB 3,000. The Turkish version of ruxolitinib tablets listed overseas, Specifications20mg*56 tablets, may be priced around RMB 8,000 per box (the price may fluctuate due to exchange rates). There are also ruxolitinib tablets produced in other countries. For example, the price of 5mg*50 tablets produced by Bangladesh Yaopin International may be around 1,400 yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of domestic and foreign original drugs.